CLAIMS

[Claim 1]

Use of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof

[Chemical Formula 1]



(I)

[wherein,

carbon marked with * is asymmetric carbon; and

A represents a group represented by general formulae (IIa), (IIb) or (IIc):

[Chemical Formula 2]



(I I a)



(I I b)



(I I c)

wherein R^1 represents a methyl group or an ethyl group optionally substituted with a halogen atom,

R^2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,

each R^3 independently represents a methyl group or an ethyl group, and

n represents 1 or 2.],

in producing a medicine for treatment or prevention of peripheral neuropathies.

[Claim 2]

The use according to claim 1, wherein A is the group represented by general formula (IIa).

[Claim 3]

The use according to claim 1, wherein A is the group represented by general formulae (IIb) or (IIc).

[Claim 4]

The use according to claim 1, wherein A is the group represented by general formula (IIa) and the stereochemical configuration of the asymmetric carbon marked with * is S.

[Claim 5]

The use according to any one of claims 1 to 4, wherein R^1 represents a methyl group or an ethyl group optionally substituted with a fluorine atom.

[Claim 6]

The use according to any one of claims 1 to 4, wherein R^1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

[Claim 7]

Use of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof

[Chemical Formula 3]



(I)

[wherein,

carbon marked with * is asymmetric carbon; and

A represents a group represented by general formulae (IIa), (IIb) or (IIc):

[Chemical Formula 4]



(IIa)



(IIb)



(IIc)

wherein R^1 represents a methyl group or an ethyl group optionally substituted with a halogen atom,

R^2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,

each R^3 independently represents a methyl group or an ethyl group, and

n represents 1 or 2.],

in producing a medicine for treatment or prevention of drug-induced peripheral neuropathies.

[Claim 8]

The use according to claim 7, wherein A is the group represented by general formula (IIa).

[Claim 9]

The use according to claim 7, wherein A is the group represented by general formulae (IIb) or (IIc).

[Claim 10]

The use according to claim 7, wherein A is the group represented by general formula (IIa), and the stereochemical configuration of the asymmetric carbon marked with * is S.

[Claim 11]

The use according to any one of claims 7 to 10, wherein R^1 represents a methyl group or an ethyl group optionally substituted with a fluorine atom.

[Claim 12]

The use according to any one of claims 7 to 10, wherein R^1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

[Claim 13]

The use according to any one of claims 7 to 12, wherein the drug-induced peripheral neuropathies are at least one type selected from anticancer agent-induced peripheral neuropathy, antiviral agent-induced peripheral neuropathy, antimicrobial agent-induced peripheral neuropathy, antitubercular agent-induced peripheral neuropathy, antiarrhythmic agent-induced peripheral neuropathy, lipid-lowering drug-induced peripheral neuropathy, immunosuppressive drug-induced peripheral neuropathy, gout therapeutic agent-induced peripheral neuropathy and peripheral neuropathies induced by other drugs.

[Claim 14]

Use of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof

[Chemical Formula 5]



(I)

[wherein,

carbon marked with * is asymmetric carbon; and

A represents a group represented by general formulae (IIa), (IIb) or (IIc):

[Chemical Formula 6]



(II a)



(II b)



(II c)

wherein R^1 represents a methyl group or an ethyl group optionally substituted with a halogen atom,

R^2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,

each R^3 independently represents a methyl group or an ethyl group, and

n represents 1 or 2.],

in producing a medicine for treatment or prevention of autoimmune peripheral neuropathies.

[Claim 15]

The use according to claim 14, wherein A is the group represented by general formula (IIa).

[Claim 16]

The use according to claim 14, wherein A is the group represented by general formulae (IIb) or (IIc).

[Claim 17]

The use according to claim 14, wherein A is the group represented by general formula (IIa), and the stereochemical configuration of the asymmetric carbon marked with * is S.

[Claim 18]

The use according to any one of claims 14 to 17, wherein R^1 represents a methyl group or an ethyl group optionally substituted with a fluorine atom.

[Claim 19]

The use according to any one of claims 14 to 17, wherein R^1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

[Claim 20]

The use according to any one of claims 14 to 19, wherein autoimmune peripheral neuropathies are at least one type selected from Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy and paraproteinemic neuropathy.

[Claim 21]

Use of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof

[Chemical Formula 7]



(I)

[wherein,

carbon marked with * is asymmetric carbon; and

A represents a group represented by general formulae (IIa), (IIb) or (IIc):

[Chemical Formula 8]



(IIa)



(IIb)



(IIc)

wherein R^1 represents a methyl group or an ethyl group optionally substituted with a halogen atom,

R^2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,

each R^3 independently represents a methyl group or an ethyl group, and

n represents 1 or 2.],

in producing a medicine for treatment or prevention of metabolic peripheral neuropathies.

[Claim 22]

The use according to claim 21, wherein A is the group represented by general formula (IIa).

[Claim 23]

The use according to claim 21, wherein A is the group represented by general formulae (IIb) or (IIc).

[Claim 24]

The use according to claim 21, wherein A is the group represented by general formula (IIa), and the stereochemical configuration of the asymmetric carbon marked with * is S.

[Claim 25]

The use according to any one of claims 21 to 24, wherein R^1 represents a methyl group or an ethyl group optionally substituted with a fluorine atom.

[Claim 26]

The use according to any one of claims 21 to 24, wherein R^1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

[Claim 27]

The use according to any one of claims 21 to 26, wherein metabolic peripheral neuropathies are at least one type selected from diabetic peripheral neuropathy, uremic peripheral neuropathy, collagen-peripheral neuropathy and vitamin deficiency peripheral neuropathy.

[Claim 28]

Use of a cyclic amine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof

[Chemical Formula 9]



(I)

[wherein,

carbon marked with * is asymmetric carbon; and

A represents a group represented by general formulae (IIa), (IIb) or (IIc):

[Chemical Formula 10]



(I I a)



(I I b)



(I I c)

wherein R^1 represents a methyl group or an ethyl group optionally substituted with a halogen atoms,

R^2 represents a hydrogen atom or an alkylcarbonyl group having 2 to 5 carbon atoms,

each R^3 independently represents a methyl group or an ethyl group, and

n represents 1 or 2.],

in producing a medicine for treatment or prevention of hereditary peripheral neuropathies.

[Claim 29]

The use according to claim 28, wherein A is the group represented by general formula (IIa).

[Claim 30]

The use according to claim 28, wherein A is the group represented by general formulae (IIb) or (IIc).

[Claim 31]

The use according to claim 28, wherein A is the group represented by general formula (IIa), and the stereochemical configuration of the asymmetric carbon marked with * is S.

[Claim 32]

The use according to any one of claims 28 to 31, wherein R^1 represents a methyl group or an ethyl group optionally substituted with a fluorine atom.

[Claim 33]

The use according to any one of claims 28 to 31, wherein R^1 is a methyl group, an ethyl group, a difluoromethyl group or a 2,2,2-trifluoroethyl group.

[Claim 34]

The use according to any one of claims 28 to 33, wherein the hereditary peripheral neuropathies are at least one type selected from Charcot-Marie-Tooth disease, familial amyloid polyneuropathy, hereditary neuropathy to pressure palsies (HNPP) and hereditary neuralgic amyotrophy.